Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses (1 mg as Drinking Solution, and 5, 20, 60, 150, 300, 500 mg as Tablets) of BI 1021958 in Healthy Male Volunteers (Placebo-controlled, Randomised and Single Blind Within Dose Groups), Including Investigation of the Effect of Food on the Bioavailability of BI 1021958 (Open-label, Randomised, Two-way Cross-over)
Latest Information Update: 20 Apr 2016
At a glance
- Drugs BI 1021958 (Primary)
- Indications Asthma
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 12 Mar 2016 Results presented at the 117th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
- 09 Nov 2013 New trial record